AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Advanced Dupuytren's Disease
Interventions
BIOLOGICAL

AA4500

Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.

Trial Locations (15)

10021

Hospital for Special Surgery, New York

11794

SUNY Stony Brook - Department of Orthopedics, Stony Brook

16550

Hand Microsurgery & Reconstructive Orthopaedics, Erie

16801

University Orthopedics Center, State College

30342

The Hand and Upper Extremity Center of Georgia, P.C., Atlanta

46260

The Indiana Hand Center, Indianapolis

55431

TRIA Orthopaedic Center, Minneapolis

61107

Rockford Orthopedic Associates, Ltd., Rockford

73109

Health Research Institute, Oklahoma City

80210

Hand Surgery Associates, PC, Denver

90095

100 UCLA Medical Plaza, Suite 305, Los Angeles

94304

Hand Surgery Clinic, Palo Alto

02115

Brigham and Women's Hospital, Department of Orthopedic Surgery, Boston

02462

Newton-Wellesley Hospital, Newton

02905

Department of Orthopaedics, Brown University, Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY